The DOI matches its Crossref record; 144 of the 144 references it cites were found in a registry or an index.
The “Cyclopropyl Fragment” is a Versatile Player that Frequently Appears in Preclinical/Clinical Drug Molecules
Open accessAbstract
Recently, there has been an increasing use of the cyclopropyl ring in drug development to transition drug candidates from the preclinical to clinical stage. Important features of the cyclopropane ring are, the (1) coplanarity of the three carbon atoms, (2) relatively shorter (1.51 Å) C–C bonds, (3) enhanced π-character of C–C bonds, and (4) C–H bonds are shorter and stronger than those in alkanes. The present review will focus on the contributions that a cyclopropyl ring makes to the properties of drugs containing it. Consequently, the cyclopropyl ring addresses multiple roadblocks that can occur during drug discovery such as (a) enhancing potency, (b) reducing off-target effects, (c) increasing metabolic stability, (d) increasing brain permeability, (e) decreasing plasma clearance, (f) contributing to an entropically more favorable binding to the receptor, (g) conformational restriction of peptides/peptidomimetics to prevent proteolytic hydrolysis, and (h) altering drug p K a to reduce its P-glycoprotein efflux ratio.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Ivanov, I. I., McKenzie, B. S., Zhou, L., Tadokoro, C. E., Lepelley, A., Lafaille, J. J., Cua, D. J., & Littman, D. R. (2006) · Cell · doi:10.1016/j.cell.2006.07.035 · Cited by 5,145
Escape from Flatland: Increasing Saturation as an Approach to Improving Clinical Success
Lovering, F., Bikker, J., & Humblet, C. (2009) · Journal of Medicinal Chemistry · doi:10.1021/jm901241e · Cited by 4,495
DrugBank: a comprehensive resource for in silico drug discovery and exploration
Wishart, D. S. (2006) · Nucleic Acids Research · doi:10.1093/nar/gkj067 · Cited by 3,892
Bond Dissociation Energies of Organic Molecules
Blanksby, S. J., & Ellison, G. B. (2003) · ChemInform · doi:10.1002/chin.200324299 · Cited by 3,376
Ethylene Biosynthesis and its Regulation in Higher Plants
Yang, S. F., & Hoffman, N. E. (1984) · Annual Review of Plant Physiology · doi:10.1146/annurev.pp.35.060184.001103 · Cited by 3,325
Advances in methods and algorithms in a modern quantum chemistry program package
Shao, Y., Molnar, L. F., Jung, Y., Kussmann, J., Ochsenfeld, C., Brown, S. T., Gilbert, A. T. B., Slipchenko, L. V., Levchenko, S. V., O’Neill, D. P., et al. (2006) · Phys. Chem. Chem. Phys. · doi:10.1039/b517914a · Cited by 2,799
Rings in Drugs: Miniperspective
Taylor, R. D., MacCoss, M., & Lawson, A. D. G. (2014) · Journal of Medicinal Chemistry · doi:10.1021/jm4017625 · Cited by 2,543
Honigberg, L. A., Smith, A. M., Sirisawad, M., Verner, E., Loury, D., Chang, B., Li, S., Pan, Z., Thamm, D. H., Miller, R. A., et al. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1004594107 · Cited by 1,561
Membrane-anchored aspartyl protease with Alzheimer's disease β-secretase activity
Yan, R., Bienkowski, M. J., Shuck, M. E., Miao, H., Tory, M. C., Pauley, A. M., Brashler, J. R., Stratman, N. C., Mathews, W. R., Buhl, A. E., et al. (1999) · Nature · doi:10.1038/990107 · Cited by 1,438
Aromatic substituent constants for structure-activity correlations
Hansch, C., Leo, A., Unger, S. H., Kim, K. H., Nikaitani, D., & Lien, E. J. (1973) · Journal of Medicinal Chemistry · doi:10.1021/jm00269a003 · Cited by 1,262
Cabozantinib in Progressive Medullary Thyroid Cancer
Elisei, R., Schlumberger, M. J., Müller, S. P., Schöffski, P., Brose, M. S., Shah, M. H., Licitra, L., Jarzab, B., Medvedev, V., Kreissl, M. C., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.48.4659 · Cited by 1,217
Targeting polo-like kinase 1 for cancer therapy
Strebhardt, K., & Ullrich, A. (2006) · Nature Reviews Cancer · doi:10.1038/nrc1841 · Cited by 841
BI 2536, a Potent and Selective Inhibitor of Polo-like Kinase 1, Inhibits Tumor Growth In Vivo
Steegmaier, M., Hoffmann, M., Baum, A., Lénárt, P., Petronczki, M., Krššák, M., Gürtler, U., Garin-Chesa, P., Lieb, S., Quant, J., et al. (2007) · Current Biology · doi:10.1016/j.cub.2006.12.037 · Cited by 834
Abnormal Morphogenesis But Intact IKK Activation in Mice Lacking the IKKα Subunit of IκB Kinase
Hu, Y., Baud, V., Delhase, M., Zhang, P., Deerinck, T., Ellisman, M., Johnson, R., & Karin, M. (1999) · Science · doi:10.1126/science.284.5412.316 · Cited by 823
Unravelling hepatitis C virus replication from genome to function
Lindenbach, B. D., & Rice, C. M. (2005) · Nature · doi:10.1038/nature04077 · Cited by 820
A Classification of Antiarrhythmic Actions Reassessed After a Decade of New Drugs
WILLIAMS, E. M. V. (1984) · The Journal of Clinical Pharmacology · doi:10.1002/j.1552-4604.1984.tb01822.x · Cited by 818
1,8-Naphthyridine Derivatives. A New Class of Chemotherapeutic Agents
Lesher, G. Y., Froelich, E. J., Gruett, M. D., Bailey, J. H., & Brundage, R. P. (1962) · Journal of Medicinal and Pharmaceutical Chemistry · doi:10.1021/jm01240a021 · Cited by 766
The Concept of Strain in Organic Chemistry
Wiberg, K. B. (1986) · Angewandte Chemie International Edition in English · doi:10.1002/anie.198603121 · Cited by 745
Nicotinic receptors: allosteric transitions and therapeutic targets in the nervous system
Taly, A., Corringer, P.-J., Guedin, D., Lestage, P., & Changeux, J.-P. (2009) · Nature Reviews Drug Discovery · doi:10.1038/nrd2927 · Cited by 703
IκB kinases: key regulators of the NF-κB pathway
Yamamoto, Y., & Gaynor, R. B. (2004) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2003.12.003 · Cited by 640
Augeri, D. J., Robl, J. A., Betebenner, D. A., Magnin, D. R., Khanna, A., Robertson, J. G., Wang, A., Simpkins, L. M., Taunk, P., Huang, Q., et al. (2005) · Journal of Medicinal Chemistry · doi:10.1021/jm050261p · Cited by 624
A Comprehensive Listing of Bioactivation Pathways of Organic Functional Groups
Kalgutkar, A., Gardner, I., Obach, R., Shaffer, C., Callegari, E., Henne, K., Mutlib, A., Dalvie, D., Lee, J., Nakai, Y., et al. (2005) · Current Drug Metabolism · doi:10.2174/1389200054021799 · Cited by 616
Soluble epoxide hydrolase as a therapeutic target for cardiovascular diseases
Imig, J. D., & Hammock, B. D. (2009) · Nature Reviews Drug Discovery · doi:10.1038/nrd2875 · Cited by 614
SAK/PLK4 Is Required for Centriole Duplication and Flagella Development
Bettencourt-Dias, M., Rodrigues-Martins, A., Carpenter, L., Riparbelli, M., Lehmann, L., Gatt, M. K., Carmo, N., Balloux, F., Callaini, G., & Glover, D. M. (2005) · Current Biology · doi:10.1016/j.cub.2005.11.042 · Cited by 600
Property-Based Design: Optimization of Drug Absorption and Pharmacokinetics
van de Waterbeemd, H., Smith, D. A., Beaumont, K., & Walker, D. K. (2001) · Journal of Medicinal Chemistry · doi:10.1021/jm000407e · Cited by 599
Menear, K. A., Adcock, C., Boulter, R., Cockcroft, X.-L., Copsey, L., Cranston, A., Dillon, K. J., Drzewiecki, J., Garman, S., Gomez, S., et al. (2008) · Journal of Medicinal Chemistry · doi:10.1021/jm8001263 · Cited by 584
Bonding Properties of Cyclopropane and Their Chemical Consequences
de Meijere, A. (1979) · Angewandte Chemie International Edition in English · doi:10.1002/anie.197908093 · Cited by 574
p38 MAPK signalling cascades in inflammatory disease
Herlaar, E., & Brown, Z. (1999) · Molecular Medicine Today · doi:10.1016/s1357-4310(99)01544-0 · Cited by 564
Kim, G., Ison, G., McKee, A. E., Zhang, H., Tang, S., Gwise, T., Sridhara, R., Lee, E., Tzou, A., Philip, R., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-0887 · Cited by 528
A DNA Hypomethylation Signature Predicts Antitumor Activity of LSD1 Inhibitors in SCLC
Mohammad, H. P., Smitheman, K. N., Kamat, C. D., Soong, D., Federowicz, K. E., Van Aller, G. S., Schneck, J. L., Carson, J. D., Liu, Y., Butticello, M., et al. (2015) · Cancer Cell · doi:10.1016/j.ccell.2015.06.002 · Cited by 504
The discovery of odanacatib (MK-0822), a selective inhibitor of cathepsin K
Gauthier, J. Y., Chauret, N., Cromlish, W., Desmarais, S., Duong, L. T., Falgueyret, J.-P., Kimmel, D. B., Lamontagne, S., Léger, S., LeRiche, T., et al. (2008) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2007.12.047 · Cited by 477
Structural and functional diversity of native brain neuronal nicotinic receptors
Gotti, C., Clementi, F., Fornari, A., Gaimarri, A., Guiducci, S., Manfredi, I., Moretti, M., Pedrazzi, P., Pucci, L., & Zoli, M. (2009) · Biochemical Pharmacology · doi:10.1016/j.bcp.2009.05.024 · Cited by 469
Structural Basis for the Activity of Drugs that Inhibit Phosphodiesterases
Card, G. L., England, B. P., Suzuki, Y., Fong, D., Powell, B., Lee, B., Luu, C., Tabrizizad, M., Gillette, S., Ibrahim, P. N., et al. (2004) · Structure · doi:10.1016/j.str.2004.10.004 · Cited by 432
New and unusual scaffolds in medicinal chemistry
Marson, C. M. (2011) · Chemical Society Reviews · doi:10.1039/c1cs15119c · Cited by 413
Rudolph, D., Steegmaier, M., Hoffmann, M., Grauert, M., Baum, A., Quant, J., Haslinger, C., Garin-Chesa, P., & Adolf, G. R. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-2445 · Cited by 398
Binda, C., Li, M., Hubálek, F., Restelli, N., Edmondson, D. E., & Mattevi, A. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1633804100 · Cited by 397
Daluge, S. M., Good, S. S., Faletto, M. B., Miller, W. H., St Clair, M. H., Boone, L. R., Tisdale, M., Parry, N. R., Reardon, J. E., Dornsife, R. E., et al. (1997) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.41.5.1082 · Cited by 384
Cox, C. D., Breslin, M. J., Whitman, D. B., Schreier, J. D., McGaughey, G. B., Bogusky, M. J., Roecker, A. J., Mercer, S. P., Bednar, R. A., Lemaire, W., et al. (2010) · Journal of Medicinal Chemistry · doi:10.1021/jm100541c · Cited by 379
Hypoalgesia and altered inflammatory responses in mice lacking kinin B1 receptors
Pesquero, J. B., Araujo, R. C., Heppenstall, P. A., Stucky, C. L., Silva, J. A., Walther, T., Oliveira, S. M., Pesquero, J. L., Paiva, A. C. M., Calixto, J. B., et al. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.120035997 · Cited by 376
Qian, F., Engst, S., Yamaguchi, K., Yu, P., Won, K.-A., Mock, L., Lou, T., Tan, J., Li, C., Tam, D., et al. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-4889 · Cited by 350
Buprenorphine: A Unique Drug with Complex Pharmacology
Lutfy, K., & Cowan, A. (2004) · Current Neuropharmacology · doi:10.2174/1570159043359477 · Cited by 345
Kropp, H., Sundelof, J. G., Hajdu, R., & Kahan, F. M. (1982) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.22.1.62 · Cited by 339
Howard, S., Berdini, V., Boulstridge, J. A., Carr, M. G., Cross, D. M., Curry, J., Devine, L. A., Early, T. R., Fazal, L., Gill, A. L., et al. (2009) · Journal of Medicinal Chemistry · doi:10.1021/jm800984v · Cited by 333
Thienamycin: development of imipenem-cilastatin
Kahan, F. M., Kropp, H., Sundelof, J. G., & Birnbaum, J. (1983) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/12.suppl_d.1 · Cited by 313
Carbapenems, a new class of beta-lactam antibiotics
Birnbaum, J., Kahan, F. M., Kropp, H., & Macdonald, J. S. (1985) · The American Journal of Medicine · doi:10.1016/0002-9343(85)90097-x · Cited by 301
The histamine H3receptor: an attractive target for the treatment of cognitive disorders
Esbenshade, T. A., Browman, K. E., Bitner, R. S., Strakhova, M., Cowart, M. D., & Brioni, J. D. (2008) · British Journal of Pharmacology · doi:10.1038/bjp.2008.147 · Cited by 296
Link, J. O., Taylor, J. G., Xu, L., Mitchell, M., Guo, H., Liu, H., Kato, D., Kirschberg, T., Sun, J., Squires, N., et al. (2014) · Journal of Medicinal Chemistry · doi:10.1021/jm401499g · Cited by 295
Okamoto, K., Kodama, K., Takase, K., Sugi, N. H., Yamamoto, Y., Iwata, M., & Tsuruoka, A. (2013) · Cancer Letters · doi:10.1016/j.canlet.2013.07.007 · Cited by 288
Distinct binding mode of multikinase inhibitor lenvatinib revealed by biochemical characterization.
Okamoto, K., Ikemori-Kawada, M., Jestel, A., von König, K., Funahashi, Y., Matsushima, T., Tsuruoka, A., Inoue, A., & Matsui, J. (2015) · ACS Medicinal Chemistry Letters · doi:10.1021/ml500394m · Cited by 285
VAN GIEZEN, J. J. J., NILSSON, L., BERNTSSON, P., WISSING, B. M., GIORDANETTO, F., TOMLINSON, W., & GREASLEY, P. J. (2009) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2009.03527.x · Cited by 284
Venkatraman, S., Bogen, S. L., Arasappan, A., Bennett, F., Chen, K., Jao, E., Liu, Y.-T., Lovey, R., Hendrata, S., Huang, Y., et al. (2006) · Journal of Medicinal Chemistry · doi:10.1021/jm060325b · Cited by 281
Ren, J., Milton, J., Weaver, K. L., Short, S. A., Stuart, D. I., & Stammers, D. K. (2000) · Structure · doi:10.1016/s0969-2126(00)00513-x · Cited by 265
Auclair, A. L., Martel, J. C., Assié, M. B., Bardin, L., Heusler, P., Cussac, D., Marien, M., Newman-Tancredi, A., O'Connor, J. A., & Depoortère, R. (2013) · Neuropharmacology · doi:10.1016/j.neuropharm.2013.02.024 · Cited by 263
Antiandrogenic Effect of Spirolactones: Mechanism of Action
CORVOL, P., MICHAUD, A., MENARD, J., FREIFELD, M., & MAHOUDEAU, J. (1975) · Endocrinology · doi:10.1210/endo-97-1-52 · Cited by 259
Zafra, F., Gomeza, J., Olivares, L., Aragón, C., & Giménez, C. (1995) · European Journal of Neuroscience · doi:10.1111/j.1460-9568.1995.tb01125.x · Cited by 259
Springthorpe, B., Bailey, A., Barton, P., Birkinshaw, T. N., Bonnert, R. V., Brown, R. C., Chapman, D., Dixon, J., Guile, S. D., Humphries, R. G., et al. (2007) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2007.07.057 · Cited by 235
Millan, M. J. (2005) · Psychopharmacology · doi:10.1007/s00213-005-2199-1 · Cited by 221
Glycine transporters as novel therapeutic targets in schizophrenia, alcohol dependence and pain
Harvey, R. J., & Yee, B. K. (2013) · Nature Reviews Drug Discovery · doi:10.1038/nrd3893 · Cited by 214
Foote, K. M., Blades, K., Cronin, A., Fillery, S., Guichard, S. S., Hassall, L., Hickson, I., Jacq, X., Jewsbury, P. J., McGuire, T. M., et al. (2013) · Journal of Medicinal Chemistry · doi:10.1021/jm301859s · Cited by 214
Discovery and Development of Simeprevir (TMC435), a HCV NS3/4A Protease Inhibitor
Rosenquist, Å., Samuelsson, B., Johansson, P.-O., Cummings, M. D., Lenz, O., Raboisson, P., Simmen, K., Vendeville, S., de Kock, H., Nilsson, M., et al. (2014) · Journal of Medicinal Chemistry · doi:10.1021/jm401507s · Cited by 213
Crystal structure of the human OX2 orexin receptor bound to the insomnia drug suvorexant
Yin, J., Mobarec, J. C., Kolb, P., & Rosenbaum, D. M. (2015) · Nature · doi:10.1038/nature14035 · Cited by 213
Discovery of MK-5172, a Macrocyclic Hepatitis C Virus NS3/4a Protease Inhibitor
Harper, S., McCauley, J. A., Rudd, M. T., Ferrara, M., DiFilippo, M., Crescenzi, B., Koch, U., Petrocchi, A., Holloway, M. K., Butcher, J. W., et al. (2012) · ACS Medicinal Chemistry Letters · doi:10.1021/ml300017p · Cited by 201
Discovery of a Highly Potent and Selective MEK Inhibitor: GSK1120212 (JTP-74057 DMSO Solvate)
Abe, H., Kikuchi, S., Hayakawa, K., Iida, T., Nagahashi, N., Maeda, K., Sakamoto, J., Matsumoto, N., Miura, T., Matsumura, K., et al. (2011) · ACS Medicinal Chemistry Letters · doi:10.1021/ml200004g · Cited by 196
Discovery of Vaniprevir (MK-7009), a Macrocyclic Hepatitis C Virus NS3/4a Protease Inhibitor
McCauley, J. A., McIntyre, C. J., Rudd, M. T., Nguyen, K. T., Romano, J. J., Butcher, J. W., Gilbert, K. F., Bush, K. J., Holloway, M. K., Swestock, J., et al. (2010) · Journal of Medicinal Chemistry · doi:10.1021/jm9015526 · Cited by 178
Pogozheva, I. D., Lomize, A. L., & Mosberg, H. I. (1998) · Biophysical Journal · doi:10.1016/s0006-3495(98)77552-6 · Cited by 177
Bart, G. B., Schluger, J. H., Borg, L., Ho, A., Bidlack, J. M., & Kreek, M. J. (2005) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300811 · Cited by 162
MRP1 and its role in anticancer drug resistance
Lu, J. F., Pokharel, D., & Bebawy, M. (2015) · Drug Metabolism Reviews · doi:10.3109/03602532.2015.1105253 · Cited by 160
Cumming, J. N., Smith, E. M., Wang, L., Misiaszek, J., Durkin, J., Pan, J., Iserloh, U., Wu, Y., Zhu, Z., Strickland, C., et al. (2012) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2012.02.013 · Cited by 160
Staudinger, H., & Ruzicka, L. (1924) · Helvetica Chimica Acta · doi:10.1002/hlca.19240070124 · Cited by 159
Metabolically Stable tert -Butyl Replacement
Barnes‐Seeman, D., Jain, M., Bell, L., Ferreira, S. A., Cohen, S., Chen, X.-H., Amin, J., Snodgrass, B., & Hatsis, P. (2013) · ACS Medicinal Chemistry Letters · doi:10.1021/ml400045j · Cited by 149
Involvement of DPP‐IV catalytic residues in enzyme–saxagliptin complex formation
Metzler, W. J., Yanchunas, J., Weigelt, C. A., Kish, K., Klei, H. E., Xie, D., Zhang, Y., Corbett, M. J., Tamura, J. K., He, B., et al. (2008) · Protein Science · doi:10.1110/ps.073253208 · Cited by 141
Feinberg, A. P., Creese, I., & Snyder, S. H. (1976) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.73.11.4215 · Cited by 135
NK3 receptor antagonists: the next generation of antipsychotics?
Spooren, W. P. J. M., Riemer, C., & Meltzer, H. Y. (2005) · Nature Reviews Drug Discovery · doi:10.1038/nrd1905 · Cited by 129
Emerging anti-insomnia drugs: tackling sleeplessness and the quality of wake time
Wafford, K. A., & Ebert, B. (2008) · Nature Reviews Drug Discovery · doi:10.1038/nrd2464 · Cited by 122
Farid, N. A., McIntosh, M., Garofolo, F., Wong, E. Y. K., Shwajch, A., Kennedy, M. J., Young, M., Sarkar, P., Kawabata, K., Takahashi, M., et al. (2006) · Rapid Communications in Mass Spectrometry · doi:10.1002/rcm.2813 · Cited by 122
Ferreira, J., Campos, M. M., Araújo, R. C., Bäder, M., Pesquero, J. B., & Calixto, J. Β. (2002) · Neuropharmacology · doi:10.1016/s0028-3908(02)00311-8 · Cited by 119
Sampson, P. B., Liu, Y., Patel, N. K., Fehér, M., Forrest, B., Li, S.-W., Edwards, L. G., Laufer, R. S., Lang, Y., Ban, F., et al. (2014) · Journal of Medicinal Chemistry · doi:10.1021/jm500537u · Cited by 116
Lou, Y. C., Han, X., Kuglstatter, A., Kondru, R. K., Sweeney, Z. K., Soth, M., McIntosh, J. E., Litman, R., Suh, J. M., Koçer, B., et al. (2014) · Journal of Medicinal Chemistry · doi:10.1021/jm500305p · Cited by 114
Magnin, D. R., Robl, J. A., Sulsky, R. B., Augeri, D. J., Huang, Y., Simpkins, L. M., Taunk, P. C., Betebenner, D. A., Robertson, J. G., Abboa‐Offei, B. E., et al. (2004) · Journal of Medicinal Chemistry · doi:10.1021/jm049924d · Cited by 108
Nakagawa, T., Tohyama, O., Yamaguchi, A., Matsushima, T., Takahashi, K., Funasaka, S., Shirotori, S., Asada, M., & Obaishi, H. (2009) · Cancer Science · doi:10.1111/j.1349-7006.2009.01343.x · Cited by 106
Betschart, C., Hintermann, S., Behnke, D., Cotesta, S., Fendt, M., Gee, C. E., Jacobson, L. H., Laue, G., Ofner, S., Chaudhari, V. D., et al. (2013) · Journal of Medicinal Chemistry · doi:10.1021/jm4007627 · Cited by 105
PDE4 inhibitors: a review of current developments (2005 – 2009)
Pagès, L., Gavaldà, A., & Lehner, M. D. (2009) · Expert Opinion on Therapeutic Patents · doi:10.1517/13543770903313753 · Cited by 104
Gentles, R. G., Ding, M., Bender, J. A., Bergstrom, C. P., Grant-Young, K. A., Hewawasam, P., Hudyma, T. W., Martin, S. W., Nickel, A., Regueiro‐Ren, A., et al. (2014) · Journal of Medicinal Chemistry · doi:10.1021/jm4016894 · Cited by 103
Veillette, A., Id, H., & Bolen, J. B. (1988) · PubMed · Cited by 103
Fleischmann, R., Kerr, B. M., Yeh, L., Suster, M., Shen, Z., Polvent, E., Hingorani, V. N., Quart, B. D., Manhard, K. J., Miner, J. N., et al. (2014) · Rheumatology · doi:10.1093/rheumatology/ket487 · Cited by 102
Labelle, M., Belley, M. L., Gareau, Y., GAUTHIER, J. Y., Guay, D., Gordon, R., Grossman, S. G., Jones, T. R., LEBLANC, Y., McAuliffe, M., et al. (1995) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/0960-894x(95)00023-m · Cited by 100
Drospirenone, a progestogen with antimineralocorticoid properties: a short review
Oelkers, W. (2003) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2003.10.030 · Cited by 98
Högberg, M., Sahlberg, C., Engelhardt, P., Noréen, R., Kangasmetsä, J., Johansson, N. G., Öberg, B. F., Vrang, L., Zhang, H., Sahlberg, B.-L., et al. (1999) · Journal of Medicinal Chemistry · doi:10.1021/jm990095j · Cited by 97
Holgate, S. T. (2005) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0706272 · Cited by 93
Yoshida, Y., Naoe, Y., Terauchi, T., Ozaki, F., Doko, T., Takemura, A., Tanaka, T., Sorimachi, K., Beuckmann, C. T., Suzuki, M., et al. (2015) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5b00217 · Cited by 91
IκB kinase inhibitors for treating autoimmune and inflammatory disorders: potential and challenges
Strnad, J., & Burke, J. R. (2007) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2007.01.005 · Cited by 89
Turner, J. R., Castellano, L. M., & Blendy, J. A. (2010) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.110.166280 · Cited by 88
Futatsugi, K., Kung, D. W., Orr, S. T. M., Cabral, S., Hepworth, D., Aspnes, G., Bader, S., Bian, J., Boehm, M., Carpino, P. A., et al. (2015) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5b01006 · Cited by 88
Synthesis and biological evaluations of quinoline-based HMG-CoA reductase inhibitors
Suzuki, M., Iwasaki, H., Fujikawa, Y., Kitahara, M., Sakashita, M., & Sakoda, R. (2001) · Bioorganic & Medicinal Chemistry · doi:10.1016/s0968-0896(01)00198-5 · Cited by 88
Hoveyda, H. R., Marsault, É., Gagnon, R., Mathieu, A. P., Vézina, M., Landry, A., Wang, Z., Benakli, K., Beaubien, S., Saint‐Louis, C. J., et al. (2011) · Journal of Medicinal Chemistry · doi:10.1021/jm2007062 · Cited by 88
Identification of a potent and selective non-basic cathepsin K inhibitor
Li, C. S., Deschênes, D., Desmarais, S., Falgueyret, J., Gauthier, J. Y., Kimmel, D. B., Léger, S., Massé, F., McGrath, M. E., McKay, D. J., et al. (2006) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2005.12.071 · Cited by 88
Capodanno, D., Dharmashankar, K., & Angiolillo, D. J. (2010) · Expert Review of Cardiovascular Therapy · doi:10.1586/erc.09.172 · Cited by 86
Tec Kinases in T Cell and Mast Cell Signaling
Felices, M., Falk, M., Kosaka, Y., & Berg, L. J. (2007) · Advances in immunology · doi:10.1016/s0065-2776(06)93004-1 · Cited by 82
Smith, B. D., Kaufman, M. D., Leary, C. B., Turner, B. A., Wise, S., Ahn, Y. M., Booth, R. J., Caldwell, T. M., Ensinger, C. L., Hood, M. M., et al. (2015) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-14-1105 · Cited by 81
Davidson, J. P., Lubman, O., Rose, T., Waksman, G., & Martin, S. (2002) · Journal of the American Chemical Society · doi:10.1021/ja011746f · Cited by 80
Respiratory syncytial virus fusion inhibitors. Part 4: Optimization for oral bioavailability
Yu, K., Sin, N., Civiello, R. L., Wang, X. A., Combrink, K. D., Gülgeze, H. B., Venables, B. L., Wright, J. J. K., Dalterio, R. A., Zadjura, L. M., et al. (2006) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2006.11.063 · Cited by 78
Involvement of the Protein Tyrosine Kinase p56lck in T Cell Signaling and Thymocyte Development
Anderson, S., Levin, S. D., & Perlmutter, R. M. (1994) · Advances in immunology · doi:10.1016/s0065-2776(08)60451-4 · Cited by 77
Sarau, H. M., Griswold, D. E., Bush, B., Potts, W. M., Sandhu, P., Lundberg, D., Foley, J. J., Schmidt, D. B., Webb, E. F., Martin, L. D., et al. (2000) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)38912-8 · Cited by 77
Scola, P. M., Wang, A. X., Good, A. C., Sun, L., Combrink, K. D., Campbell, J. A., Chen, J., Tu, Y., Sin, N., Venables, B. L., et al. (2014) · Journal of Medicinal Chemistry · doi:10.1021/jm401840s · Cited by 76
Hohlfeld, J. M., Schoenfeld, K., Lavae-Mokhtari, M., Schaumann, F., Mueller, M., Bredenbroeker, D., Krug, N., & Hermann, R. (2008) · Pulmonary Pharmacology & Therapeutics · doi:10.1016/j.pupt.2008.02.002 · Cited by 71
Yip, Y. Y., Victor, F., Lamar, J., Johnson, R. B., Wang, Q. M., Barket, D., Glass, J. I., Jin, L., Liu, L., Venable, D. F., et al. (2003) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2003.09.074 · Cited by 67
Phosphodiesterase Inhibitors as Potential Cognition Enhancing Agents
Schmidt, C. J. (2010) · Current Topics in Medicinal Chemistry · doi:10.2174/156802610790411009 · Cited by 66
Hirata, K., Kotoku, M., Seki, N., Maeba, T., Maeda, K., Hirashima, S., Sakai, T., Obika, S., Hori, A., Hase, Y., et al. (2015) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.5b00253 · Cited by 62
Triple Reuptake Inhibitors: The Next Generation of Antidepressants
Marks, D., Pae, C., & Patkar, A. A. (2008) · Current Neuropharmacology · doi:10.2174/157015908787386078 · Cited by 61
Tasimelteon: A selective and unique receptor binding profile
Lavedan, C. N., Forsberg, M. A., & Gentile, A. J. (2014) · Neuropharmacology · doi:10.1016/j.neuropharm.2014.12.004 · Cited by 59
Wang, A., Dorso, C. R., Kopcho, L. M., Locke, G. A., Langish, R. A., Harstad, E. B., Shipkova, P. A., Marcinkeviciene, J. A., Hamann, L. G., & Kirby, M. (2012) · BMC Pharmacology · doi:10.1186/1471-2210-12-2 · Cited by 59
Macrocyclic BACE-1 inhibitors acutely reduce Aβ in brain after po application
Lerchner, A. M., Machauer, R., Betschart, C., Veenstra, S. J., Rueeger, H., McCarthy, C., Tintelnot‐Blomley, M., Jaton, A.-L., Rabe, S., Desrayaud, S., et al. (2009) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2009.11.092 · Cited by 58
Liu, C., Lin, J. C.-J., Wrobleski, S. T., Lin, S., Hynes, J. J., Wu, H., Dyckman, A. J., Li, T., Wityak, J., Gillooly, K. M., et al. (2010) · Journal of Medicinal Chemistry · doi:10.1021/jm100540x · Cited by 57
Kuduk, S. D., Marco, C. N. D., Chang, R. K., et al. (2006) · Journal of Medicinal Chemistry · doi:10.1021/jm061094b · Cited by 56
New quinoline NK3 receptor antagonists with CNS activity
Smith, P. W., Wyman, P. A., Lovell, P. J., Goodacre, C. J., Serafinowska, H. T., Vong, A. K. K., Harrington, F. P., Flynn, S. T., Bradley, D. M., Porter, R. A., et al. (2008) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2008.12.005 · Cited by 56
Rizzo, R. C., Wang, D., Tirado‐Rives, J., & Jorgensen, W. L. (2000) · Journal of the American Chemical Society · doi:10.1021/ja003113r · Cited by 55
Benzodiazepines as Potent and Selective Bradykinin B1 Antagonists
Wood, M. R., Kim, J. J., Han, W., Dorsey, B. D., Homnick, C. F., DiPardo, R. M., Kuduk, S. D., MacNeil, T., Murphy, K. L., Lis, E. V., et al. (2003) · Journal of Medicinal Chemistry · doi:10.1021/jm034020y · Cited by 51
Tedeschi, R. E., Tedeschi, D. H., Ames, P. L., et al. (1959) · Experimental Biology and Medicine · doi:10.3181/00379727-102-25256 · Cited by 49
Yu, K., Wang, X. A., Civiello, R. L., Trehan, A. K., Pearce, B. C., Yin, Z., Combrink, K. D., Gülgeze, H. B., Zhang, Y., Kadow, K. F., et al. (2005) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2005.11.109 · Cited by 48
Aston, N. M., Bamborough, P., Buckton, J. B., Edwards, C. D., Holmes, D. S., Jones, K. L., Patel, V. K., Smee, P. A., Somers, D. O., Vitulli, G., et al. (2009) · Journal of Medicinal Chemistry · doi:10.1021/jm9004779 · Cited by 46
Zheng, X., Hudyma, T. W., Martin, S. W., Bergstrom, C. P., Ding, M., He, F., Romine, J. L., Poss, M. A., Kadow, J. F., Chang, C., et al. (2011) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2011.03.067 · Cited by 45
Gallant, M., Aspiotis, R., Day, S., Dias, R., Dubé, D., Dubé, L., Friesen, R. W., Girard, M., Guay, D., Hamel, P., et al. (2010) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2010.09.087 · Cited by 45
Vuligonda, V., Lin, Y. H., & Chandraratna, R. A. S. (1996) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/0960-894x(95)00588-k · Cited by 43
γ-secretase inhibitors: Notch so bad
Grosveld, G. C. (2009) · Nature Medicine · doi:10.1038/nm0109-20 · Cited by 42
Synthesis and opioid receptor binding properties of a highly potent 4-hydroxy analogue of naltrexone
Wentland, M. P., Lu, Q., Lou, R., Bu, Y., Knapp, B. I., & Bidlack, J. M. (2005) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2005.02.032 · Cited by 41
Circumvention of multidrug resistance by a newly synthesized quinoline derivative, MS-073.
Sato, W., Fukazawa, N., Suzuki, T., Yusa, K., & Tsuruo, T. (1991) · PubMed · Cited by 41
Kozikowski, A. P., Eaton, J. B., Bajjuri, K. M., Chellappan, S. K., Chen, Y., Karadi, S., He, R., Caldarone, B., Manzano, M., Yuen, P., et al. (2009) · ChemMedChem · doi:10.1002/cmdc.200900079 · Cited by 36
Pharmacological inhibition of the soluble epoxide hydrolase—from mouse to man
Revermann, M. (2010) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2009.12.002 · Cited by 35
Zhang, H., Tückmantel, W., Eaton, J. B., Yuen, P., Yu, L.-F., Bajjuri, K. M., Fedolak, A., Wang, D., Ghavami, A., Caldarone, B. J., et al. (2011) · Journal of Medicinal Chemistry · doi:10.1021/jm201157c · Cited by 34
Sahu, N., Mueller, C., Fischer, A., & August, A. (2008) · The Journal of Immunology · doi:10.4049/jimmunol.180.6.3833 · Cited by 32
Liddle, J., Bamborough, P., Barker, M. D., Campos, S., Chung, C., Cousins, R. P. C., Faulder, P., Heathcote, M. L., Hobbs, H., Holmes, D. S., et al. (2012) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2012.06.065 · Cited by 28
Zhang, H.-K., Eaton, J. B., Yu, L.-F., Nys, M., Mazzolari, A., van Elk, R., Smit, A. B., Alexandrov, V., Hanania, T., Sabath, E. V., et al. (2012) · Journal of Medicinal Chemistry · doi:10.1021/jm3008739 · Cited by 27
4-cyanothiazolidides as very potent, stable inhibitors of dipeptidyl peptidase IV
Ashworth, D. M., Atrash, B., Baker, G. R., Baxter, A., Jenkins, P. D., Jones, D. M., & Szelke, M. (1996) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/s0960-894x(96)00491-x · Cited by 26
Chapter 14. Quinolone Antibacterial Agents
Cornett, J. B., & Wentland, M. P. (1986) · Annual reports in medicinal chemistry · doi:10.1016/s0065-7743(08)61124-0 · Cited by 24
Identification of an Orally Bioavailable, Potent, and Selective Inhibitor of GlyT1
Blackaby, W., Lewis, R. T., Thomson, J. L., Jennings, A. S. R., Goodacre, S. C., Street, L. J., MacLeod, A. M., Pike, A. J., Wood, S., Thomas, S., et al. (2010) · ACS Medicinal Chemistry Letters · doi:10.1021/ml1001085 · Cited by 22
Guay, D., Boulet, L., Friesen, R. W., Girard, M., Hamel, P., Huang, Z., Laliberté, F., Laliberté, S., Mancini, J. A., Muise, E. S., et al. (2008) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2008.09.009 · Cited by 20
Schiff, M. H., & Peura, D. A. (2011) · Expert Review of Gastroenterology & Hepatology · doi:10.1586/egh.11.88 · Cited by 20
Takai, K., Chiyo, N., Nakajima, T., Nariai, T., Ishikawa, C., Nakatani, S., Ikeno, A., Yamamoto, S., & Sone, T. (2015) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2015.02.076 · Cited by 17
Opioid receptor blocker shows promise in Phase II depression trial
Harrison, C. (2013) · Nature Reviews Drug Discovery · doi:10.1038/nrd4028 · Cited by 15
Novel orally active morpholine N-arylsulfonamides γ-secretase inhibitors with low CYP 3A4 liability
Josien, H. B., Bara, T. A., Rajagopalan, M., Clader, J. W., Greenlee, W. J., Favreau, L. V., Hyde, L. A., Nomeir, A. A., Parker, E. M., Song, L., et al. (2009) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2009.09.055 · Cited by 14
Garofalo, A. W. (2008) · Expert Opinion on Therapeutic Patents · doi:10.1517/13543776.18.7.693 · Cited by 13
Cyclopropane Compounds of Biological Interest
Burger, A. (1971) · Birkhäuser Basel eBooks · doi:10.1007/978-3-0348-7078-8_7 · Cited by 8
Enantiopure Cyclopropane-Bearing Pyridyldiazabicyclo[3.3.0]octanes as Selective ?4?2-nAChR Ligands
Onajole, O. K., Eaton, J. B., Lukas, R. J., Brunner, D., Thiede, L., Caldarone, B. J., & Kozikowski, A. P. (2014) · ACS Medicinal Chemistry Letters · doi:10.1021/ml500129k · Cited by 8
Allosteric MEK1/2 Inhibitors for the Treatment of Cancer: an Overview
McDermott, L. A. (2015) · Journal of Drug Research and Development · doi:10.16966/2470-1009.101 · Cited by 7
Cited by
Put a ring on it: application of small aliphatic rings in medicinal chemistry
Bauer, M. R., Di Fruscia, P., Lucas, S. C. C., Michaelides, I. N., Nelson, J. E., Storer, R. I., & Whitehurst, B. C. (2021) · RSC Medicinal Chemistry · doi:10.1039/d0md00370k · Cited by 479
Kwon, K., Simons, R. T., Nandakumar, M., & Roizen, J. L. (2022) · Chemical Reviews · doi:10.1021/acs.chemrev.1c00444 · Cited by 389
Wrobleski, S. T., Moslin, R., Lin, S., Zhang, Y., Spergel, S., Kempson, J., Tokarski, J. S., Strnad, J., Zupa-Fernandez, A., Cheng, L., et al. (2019) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.9b00444 · Cited by 382
A Survey of the Structures of US FDA Approved Combination Drugs
Das, P., Delost, M. D., Qureshi, M. H., Smith, D. T., & Njardarson, J. T. (2019) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.8b01610 · Cited by 312
Redox-Neutral Photocatalytic Cyclopropanation via Radical/Polar Crossover
Phelan, J. P., Lang, S. B., Compton, J. S., Kelly, C. B., Dykstra, R., Gutierrez, O., & Molander, G. A. (2018) · Journal of the American Chemical Society · doi:10.1021/jacs.8b05243 · Cited by 273
Metadata
- Authors
- Talele, T. T.
- Venue
- Journal of Medicinal Chemistry
- Publisher
- American Chemical Society (ACS)
- Published
- 2016-06-30
- Volume
- 59
- Issue
- 19
- Pages
- 8712-8756
- ISSN
- 0022-2623 (ISSN-L)
- 1520-4804
- OpenAlex
- W2422726141
- Cited by
- 1,023
- References
- 144
- FWCI
- 28.06
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.